Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Patient Outcomes Real World Evidence Registry (POWER): Patient Reported Outcomes in a Cohort of Canadian Adults With Severe Eosinophilic Asthma on Benralizumab.

NCT03833141 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT03833141
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03833141 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Patient Outcomes Real World Evidence Registry (POWER): Patient Reported Outcomes in a Cohort of Canadian Adults With Severe Eosinophilic Asthma on Benralizumab.
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
November 12, 2018
Completion date
May 28, 2024
Enrollment
170 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

severe eosinophilic asthma